Body composition parameters and adipokines levels in relation to bone mineral density in patients with malignant bone tumors after treatment

Abstract

Background: Recent data support the concept that adipokines, which are secreted by fat cells, are important modulators of bone metabolism. The aim of this study was to assess the relationships between body composition parameters, adipokines (leptin, adiponectin) and bone mineral density (BMD) in patients with malignant bone tumors after anticancer therapy. Procedure: The study included 35 patients (median age 14.8 years) with diagnosed malignant bone tumors treated according to obligatory protocols. Total fat mass, lean mass, bone mineral content (BMC) and BMD measurements were performed after treatment completion by dual energy-ray absorptiometry (DXA). Serum concentrations of leptin, leptin receptor and adiponectin were determined using immunoenzymatic assays. The control group consisted of 28 healthy children (median age 14.3 years). Results: Patients with bone tumor after chemotherapy had significantly higher fat mass (P<0.01), increased ratio of fat mass/lean mass (P<0.001), and a decrease (P<0.001) in total body and lumbar spine BMD compared with controls. We observed higher serum leptin concentration (P<0.01) and lower soluble leptin receptor (P<0.001) and adiponectin (P=0.01) in patients than in controls. The ratios of leptin/leptin receptor and leptin/adiponectin were about three-fold higher in patients compared with the control group (P=0.001). We found a significant positive correlation between BMD and body composition and a negative correlation between BMD and adiponectin in the patients group. Conclusions: Changes in body composition parameters coexisting with disturbed adipokine levels, especially higher levels of leptin and lower levels of adiponectin, might be associated with bone status in patients treated for malignant bone tumors. Pediatr Blood Cancer 2015;62:988-993.